Not Yet RecruitingPhase 4

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

United States852 participantsStarted 2026-06-01

Plain-language summary

The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Hospitalized or being hospitalized.
✓. Age \>/=18 yr old.
✓. Serious or suspected serious infection for which VPT or VM considered a broad-spectrum combination antibiotic backbone standard of care by clinician.
✓. Enrollment can be completed before the first dose of abx (ideally) and no later than before the second dose (alternatively).
✓. Consenting/enrollment will not clinically significantly delay abx administration.
✓. Baseline and \>/=1 prior Scr available (within 1 yr).

What they're measuring

Serum cystatin C (Scys)

Timeframe: 7 days

Trial details

NCT IDNCT07556107

SponsorBassett Healthcare

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-06-30

Contact for this trial

Amanda Hasuly

443-473-0986 amanda.hasuly@bassett.org

View on ClinicalTrials.gov More Infection trials